Clinical trials
Hepatitis clinical trials
Below are recruiting hepatitis clinical trials, each written for real people, not researchers. We’re tracking 480 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05922306RecruitingEarly Phase 1
Testing continuous vs pulsed treatment for chronic hepatitis B
This early-phase study compares two ways of giving treatment for chronic hepatitis B: continuous antiviral therapy versus pulsed treatment. It may help find a schedule that works well and is tolerable for people with hepatitis B.
Hefei, AnhuiAges 18–60 - NCT05988879Recruiting
Functional cure for hepatitis B in HIV/HBV co-infection
This trial tests whether people with both HIV and hepatitis B can achieve a functional cure for hepatitis B. It aims to see if current treatment can be stopped safely after the hepatitis B virus is no longer active.
Guangzhou, GuangdongAges 18–65 - NCT06051045Recruiting
Bulevirtide for chronic hepatitis B and D
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
StockholmAges 18 years+ - NCT06078098Recruiting
Autoimmune Hepatitis Database and Biobank Study
This study is building a database and collection of samples from people with autoimmune hepatitis in Italy. It aims to learn more about the disease and improve care.
Monza, MBAges 1 year+ - NCT07855029Recruiting
Quality of life after hepatitis B treatment outcomes
This study looks at how different outcomes of chronic hepatitis B treatment affect patients' quality of life. It includes people who have been functionally cured, those still on treatment, those who relapsed, and healthy controls to compare.
GuangzhouAges 18–65 - NCT05977283Recruiting
Follow-up study for people whose hepatitis B test improved
This study follows people with hepatitis B (HBV) blood tests that have improved over the last year. It aims to learn what happens after the hepatitis B surface antigen (HBsAg) goes down, and may help doctors better predict outcomes.
Guangzhou, GuangdongAges 18–65 - NCT05903742Recruiting
Standard care for hepatitis delta in the Netherlands
This trial focuses on improving and standardizing how hepatitis delta is cared for in the Netherlands. To take part, you must have confirmed active hepatitis delta and be an adult.
RotterdamAges 18 years+ - NCT06368882RecruitingPhase 4
Peg-interferon for hepatitis B with fatty liver
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
NingboAges 18–60 - NCT07852091RecruitingPhase 2
Combination therapy aiming for a functional cure for chronic hepatitis B
This study tests a new combination of medicines to help your immune system control the hepatitis B virus, with the goal of stopping the need for long-term treatment. It may be an option for people who have taken or are currently taking hepatitis B medications.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT07845058RecruitingPhase 2
Combination therapy for a functional cure of chronic hepatitis B
This trial tests a new combination of medicines to help your body control the hepatitis B virus without needing lifelong treatment. It aims for a 'functional cure,' which means the virus stays inactive and your liver stays healthy.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT07847710RecruitingPhase 2
Combination therapy before and after surgery for early liver cancer
This trial is testing a combination of two drugs (one that helps the immune system fight cancer and one that blocks blood vessel growth) with a special chemotherapy given directly into the liver. The goal is to shrink the tumor so it can be removed with surgery, possibly improving the chances of a cure.
Nanjing, JiangsuAges 18–75 - NCT07809802RecruitingPhase 1
Study of vorolanib tablets in people with liver problems
This study looks at how the body handles the study drug vorolanib (taken as a tablet) when your liver is impaired. It might help doctors understand the right dose for people with liver problems, and it may also benefit those who are newly diagnosed or exploring treatment options.
Changchun, JilinAges 18–70 - NCT07794514Recruiting
Comparing two drugs for liver graft-versus-host disease
This trial compares two medications, belumosudil and ruxolitinib, to see which one works better for a type of graft-versus-host disease (GVHD) that affects the liver after a stem cell transplant. GVHD happens when donor cells attack the patient's body, and this study focuses on patients whose liver GVHD has not improved with steroids or has gotten worse. The study aims to find a more effective treatment to control this condition.
Hangzhou, ZhejiangAges 12 years+ - NCT07799948Recruiting
Stent adjustment for repeated confusion after liver shunt
This study tests a procedure to narrow a stent in the liver to reduce episodes of confusion caused by toxins reaching the brain. It may help people who still have frequent confusion despite standard treatments.
Xi'an, ShaanxiAges 18 years+ - NCT06525909Recruiting
Immune status in chronic hepatitis B
This study looks at how the immune system changes over time in people with chronic hepatitis B. It will help doctors better understand the stages of the disease to guide treatment decisions.
Wuhan, HubeiAges 18–50 - NCT06586983Recruiting
Hepatitis B care closer to home in Ethiopia
This trial tests a program to bring hepatitis B care to local clinics in Ethiopia, so you may not need to travel far for treatment. It is for adults who have tested positive for hepatitis B surface antigen (HBsAg), meaning they have a current hepatitis B infection.
Addis Ababa, Addis AbabaAges 18 years+ - NCT07732114Recruiting
Liver vein vs. heart echo to check right heart function on a ventilator
This study compares a liver vein ultrasound method with a standard heart ultrasound for checking how well the right side of the heart is pumping in patients who are on a breathing machine (ventilator). If you are on a ventilator and can get a clear ultrasound of your heart and liver veins, you may be able to join.
Alexandria, Shebin El-KomAges 18 years+ - NCT06632093Recruiting
Combination therapy for advanced liver cancer after standard treatment fails
This trial tests a triple combination of liver-directed chemotherapy (HAIC) plus immunotherapy (PD-1 inhibitor) and targeted therapy (Lenvatinib) for people with advanced liver cancer that has spread into the portal vein and who have already tried and failed standard treatments.
Shenyang, LiaoningAges 18–75 - NCT07709520RecruitingPhase 2
Testing a new hepatitis B treatment in adults
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
BeijingAges 35–65 - NCT07682818RecruitingPhase 1
Petrelintide in people with liver impairment
This trial tests how a drug called petrelintide is processed in people with different levels of liver function. It may help doctors understand how to dose the drug safely for patients with liver disease, including those with type 2 diabetes.
Wroclaw, PolandAges 18–70 - NCT07677358RecruitingPhase 1
Atirmociclib in people with normal or reduced liver function
This study tests how the body handles the medicine Atirmociclib in people with different levels of liver function, from normal to moderate or severe liver disease. It helps doctors understand if the dose needs to be adjusted for people with liver problems.
Miami Lakes, FloridaAges 18 years+ - NCT06668727RecruitingPhase 1
Testing a new antibody for hepatitis B safety
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
Aarhus NAges 18–70 - NCT07667101Recruiting
Hepatitis C team care for people in supportive housing
This study tests a team-based approach — a pharmacist, doctor, and patient navigator working together — to help people living in permanent supportive housing get hepatitis C care. If you have hepatitis C and live in DESC housing, the study will check how well this team helps you through treatment over 2 years.
Seattle, WashingtonAges 18 years+ - NCT07663422RecruitingPhase 2
Treating immunotherapy-related liver inflammation with mycophenolate and prednisone
This trial tests a combination of two drugs, mycophenolate mofetil and prednisone, to treat moderate to severe liver inflammation caused by immunotherapy. The goal is to see if this treatment can help control the inflammation without needing long-term high-dose steroids.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis?
- Yes. Clin2 currently lists 480 recruiting hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.